Biocartis raises EUR 32.7M in private placement

Molecular diagnostics company Biocartis Group N.V. (Euronext:BCART) raised EUR 32.7 million ($35.1 million) through the sale of 4.1 million shares at EUR 8.05 in a private placement underwritten by Degroof Petercam, KBC Securities and Kempen & Co.

The company said the funds will support development of new tests based on its Idylla diagnostic platform. Also on Thursday, Biocartis said it granted Thermo Fisher Scientific Inc. (NYSE:TMO) U.S. distribution rights to Idylla. The companies expect to launch Idylla in the U.S. in mid-2017. ...